Tempest Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Tempest Therapeutics, Inc. (TPST) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $2.61 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00.
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $108.03, a 2909.19% increase year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.59, a 52.07% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $106.99, a 2594.96% increase from fiscal 2023.
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $3.97, a 96.92% decline from fiscal 2022.
- Tempest Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $128.79, a 11.29% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.61 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | |||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | $106.99 10-K · filed 2026-03-30 | $8.23 10-K · filed 2025-03-27 | ||||||
| 2024-09-30 | $106.99 10-Q · filed 2025-11-05 | $8.23 10-Q · filed 2024-11-12 | ||||||
| 2024-06-30 | $106.99 10-Q · filed 2025-08-11 | $8.23 10-Q · filed 2024-08-08 | ||||||
| 2024-03-31 | $108.03 10-Q · filed 2025-05-13 | $8.31 10-Q · filed 2024-05-09 | ||||||
| 2023-12-31 | $3.97 10-K · filed 2025-03-27 | |||||||
| 2023-09-30 | $4.36 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | $4.58 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | $3.59 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | $128.79 10-K · filed 2024-03-19 | |||||||
| 2022-09-30 | $266.80 10-Q · filed 2023-11-08 | |||||||
| 2022-06-30 | $428.76 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $7.49 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | $115.72 10-K · filed 2023-03-22 | |||||||
| 2021-09-30 | $107.77 10-Q · filed 2022-11-08 | |||||||
| 2021-06-30 | $18.36 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | $5.90 10-Q · filed 2022-05-13 | $6.69 10-Q · filed 2021-05-13 | ||||||
| 2020-12-31 | $4.92 10-K · filed 2022-03-29 | $13.39 10-K · filed 2021-03-29 | ||||||
| 2020-09-30 | $13.81 10-Q · filed 2020-11-09 | |||||||
| 2020-06-30 | $15.05 10-Q · filed 2020-08-10 | |||||||
| 2020-03-31 | $14.65 10-Q · filed 2020-05-08 | |||||||
| 2019-12-31 | $40.42 10-K · filed 2021-03-29 | |||||||
| 2019-09-30 | $41.50 10-Q · filed 2019-11-13 | |||||||
| 2019-06-30 | $86.07 10-Q · filed 2019-08-12 | |||||||
| 2019-03-31 | $59.41 10-Q · filed 2019-05-15 | |||||||
| 2018-12-31 | $8.54 10-K · filed 2020-03-11 | |||||||
| 2017-12-31 | $5.23 10-K · filed 2019-04-01 | $9.63 10-K · filed 2018-03-15 | ||||||
| 2016-12-31 | $19.87 10-K · filed 2017-03-02 | |||||||
| 2015-12-31 | $28.60 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |